0001209191-21-051441.txt : 20210813
0001209191-21-051441.hdr.sgml : 20210813
20210813171346
ACCESSION NUMBER: 0001209191-21-051441
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210708
FILED AS OF DATE: 20210813
DATE AS OF CHANGE: 20210813
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Galante Joseph C
CENTRAL INDEX KEY: 0001632384
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33637
FILM NUMBER: 211173327
MAIL ADDRESS:
STREET 1: 111 TENTH AVENUE
STREET 2: SUITE 200
CITY: NASHVILLE
STATE: TN
ZIP: 37203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CUMBERLAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001087294
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2525 WEST END AVENUE
STREET 2: SUITE 950
CITY: NASHVILLE,
STATE: TN
ZIP: 37203
BUSINESS PHONE: 615-255-0068
MAIL ADDRESS:
STREET 1: 2525 WEST END AVENUE
STREET 2: SUITE 950
CITY: NASHVILLE
STATE: TN
ZIP: 37203
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-07-08
0
0001087294
CUMBERLAND PHARMACEUTICALS INC
CPIX
0001632384
Galante Joseph C
2525 WEST END AVENUE
SUITE 950
NASHVILLE
TN
37203
1
0
0
0
Common Stock
2021-07-08
4
P
0
142
3.18
A
32559
D
Common Stock
2021-07-09
4
P
0
142
3.13
A
32701
D
Common Stock
2021-07-12
4
P
0
142
3.33
A
32843
D
Common Stock
2021-07-13
4
P
0
142
3.48
A
32985
D
Common Stock
2021-07-14
4
P
0
142
3.33
A
33127
D
Common Stock
2021-07-15
4
P
0
142
3.27
A
33269
D
Common Stock
2021-07-16
4
P
0
142
3.28
A
33411
D
Common Stock
2021-07-19
4
P
0
142
3.23
A
33553
D
Common Stock
2021-07-20
4
P
0
142
3.24
A
33695
D
Common Stock
2021-07-21
4
P
0
142
3.26
A
33837
D
Common Stock
2021-07-22
4
P
0
142
3.36
A
33979
D
Common Stock
2021-07-23
4
P
0
142
3.35
A
34121
D
Common Stock
2021-07-26
4
P
0
142
3.39
A
34263
D
Common Stock
2021-07-27
4
P
0
142
3.39
A
34405
D
Common Stock
2021-07-28
4
P
0
142
3.42
A
34547
D
Common Stock
2021-07-29
4
P
0
142
3.42
A
34689
D
Common Stock
2021-07-30
4
P
0
142
3.31
A
34831
D
The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021.
Joseph C. Galante by /s/ John Hamm as
attorney-in-fact
2021-08-13